BXT Stock Overview
Engages in R&D and manufacturing of thin-film (sublingual) and skin patch (transdermal) drug delivery for neurological and autoimmune diseases, enhancing patient compliance and bioavailability. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
BioNxt Solutions Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.35 |
| 52 Week High | CA$0.42 |
| 52 Week Low | CA$0.11 |
| Beta | 1.42 |
| 1 Month Change | 27.27% |
| 3 Month Change | 0.86% |
| 1 Year Change | 41.13% |
| 3 Year Change | -39.55% |
| 5 Year Change | -83.41% |
| Change since IPO | -61.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| BXT | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 4.5% | 2.0% | -0.9% |
| 1Y | 41.1% | -25.8% | 14.1% |
Return vs Industry: BXT exceeded the German Pharmaceuticals industry which returned -26.3% over the past year.
Return vs Market: BXT exceeded the German Market which returned 15.8% over the past year.
Price Volatility
| BXT volatility | |
|---|---|
| BXT Average Weekly Movement | 16.9% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: BXT's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: BXT's weekly volatility has decreased from 24% to 17% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Wolfgang Probst | www.bionxt.com |
BioNxt Solutions Inc. engages in R&D and manufacturing of thin-film (sublingual) and skin patch (transdermal) drug delivery for neurological and autoimmune diseases, enhancing patient compliance and bioavailability. It offers diagnostic screening tests, and new active pharmaceutical production and evaluation, including precision transdermal and oral dissolvable drug formulations; oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022.
BioNxt Solutions Inc. Fundamentals Summary
| BXT fundamental statistics | |
|---|---|
| Market cap | €39.38m |
| Earnings (TTM) | -€4.16m |
| Revenue (TTM) | €26.94k |
Is BXT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BXT income statement (TTM) | |
|---|---|
| Revenue | CA$42.01k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$42.01k |
| Other Expenses | CA$6.52m |
| Earnings | -CA$6.48m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.056 |
| Gross Margin | 100.00% |
| Net Profit Margin | -15,422.18% |
| Debt/Equity Ratio | -76.0% |
How did BXT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 12:57 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioNxt Solutions Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.